NCT04522843Completed
Analysis of Intestinal Defensin Expression in Acute GVHD
Analysis of Intestinal Defensin Expression in Patients With Acute Graft-versus-Host Disease (GVHD)
Source: ClinicalTrials.gov · Last updated 18 Dec 2024
Brief summary (registry, in English)
This study has the aim to analyze intestinal expression of endogenous antimicrobial peptides in patients with acute GVHD. The expression will be compared to intestinal expression of defensins in patients with colitis and patients without intestinal inflammation.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 80 (actual)
- First submitted
- 18 Aug 2020
- Start date
- 1 Sept 2018
- Primary completion date
- 30 Oct 2024
- Lead sponsor
- University of Freiburg
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT04522843
What you commit to
- Study type: Observational
- Participants enrolled: 80
- From 1 Sept 2018 to the primary completion date, 30 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- gastrointestinal cancer
Age
- age \< 18 years
Other
- lack of informed consent
Who the study is looking for
- age ≥ 18 years
- diagnostic endoscopy was performed
- diagnosis results available
- written informed consent
- ability to understand the nature of the study and the study related procedures and to comply with them
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Center- University of Freiburg Coordinator of this site? Confirm its status | Freiburg im Breisgau | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.